Note 1 - Nature of Business, Financial Condition, Basis of Presentation (Details Textual)				1 Months Ended		3 Months Ended			6 Months Ended
	Dec. 15, 2020 shares	Dec. 10, 2020 USD ($) $ / shares	Dec. 08, 2020	Feb. 11, 2021 shares	Jun. 30, 2020 USD ($) shares	Dec. 31, 2020 USD ($) shares	Sep. 30, 2020 shares	Dec. 31, 2019 USD ($)	Dec. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($)	Feb. 05, 2021 USD ($) shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance						$ 62,300,000			$ 62,300,000
Revenue from Contract with Customer, Including Assessed Tax						15,147,034		$ 3,175,236	$ 28,667,280	$ 4,615,062
Increase (Decrease) in Revenues, Percentage									377.00%	521.00%
Net Cash Provided by (Used in) Operating Activities, Total									$ (10,900,299)	$ (9,087,054)
Assets, Current, Total					$ 74,965,772	92,537,465			$ 92,537,465
Proceeds from Issuance of Common Stock						$ 29,600,000
Class of Warrant or Right, Issued During Period (in shares) | shares									403,760
Debt Conversion, Converted Instrument, Amount									$ 1,057,559
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			10
Conversion of Debt to Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 800,000
Debt Conversion, Converted Instrument, Amount		100,000
Placement Agent Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares) | shares	300,000
At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares					430,230	352,912	0
December 15, 2020 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	4,800,000
Bridge Commitment Letter [Member]
Debt Instrument, Face Amount		$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Debt Instrument, Increase in Stated Rate Upon Default, Percentage		2.00%
Subsequent Event [Member] | At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares				0
Neos Therapeutics, Inc. [Member]
Merger Agreement, Exercise Price of Stock Options (in dollars per share) | $ / shares		$ 0.95
Merger Agreement, Exchange Ratio		0.1088
Merger Agreement, Reduction in Exchange Ratio Per $100,000 of Financing Funded		0.00011
Neos Therapeutics, Inc. [Member] | Subsequent Event [Member]
Merger Agreement, Shares to be Issued, Shares (in shares) | shares											5,400,000
Merger Agreement, Shares to be Issued, Value											$ 44,200,000
Neo Stockholders [Member]
Common Stock Ownership, Percent		24.00%
Existing Company Stockholders [Member]
Common Stock Ownership, Percent		76.00%